Products classification
ABOUT US
Email:
sales@ruixibiotech.com
Tel.:
02988811435
Home > products > apis> gpcr-g-protein
Catalog name Description price
R-R-4260 CXCR2-IN-1 CAS No.1873376-49-8 CXCR2-IN-1/CAS No.1873376-49-8 is a central nervous system penetrant CXCR2 antagonist with a pIC50 of 9.3. price>
R-R-4261 AMD 3465 hexahydrobromide CAS No.185991-07-5 AMD 3465 hexahydrobromide (GENZ-644494 hexahydrobromide)/CAS No.185991-07-5 is a potent antagonist of CXCR4, inhibits binding of 12G5 mAb and CXCL12AF647 to CXCR4, with IC50s of 0.75 nM and 18 nM in SupT1 cells; AMD 3465 also potently inhibits the replication of X4 HIV strains (IC50: 1-10 nM), but has no effect on CCR5-using (R5) viruses. price>
R-R-4262 CXCR7 modulator 2 CAS No.2227426-37-9 CXCR7 modulator 2/CAS No.2227426-37-9 is a modulator of C-X-C Chemokine Receptor Type 7 (CXCR7), with a Ki of 13 nM. price>
R-R-4263 CXCR2 antagonist 8 CAS No.182498-30-2 CXCR2 antagonist 8/CAS No.182498-30-2 is a potent and selective CXCR2 antagonist. CXCR2 antagonist 8 can be used for insulin resistance research. price>
R-R-4264 CXCR7 antagonist-1 hydrochloride CAS No.2990472-61-0 CXCR7 antagonist-1 hydrochloride/CAS No.2990472-61-0 is a CXCR7 antagonist that inhibits the binding of the SDF-1 chemokine (also known as the CXCL12 chemokine) or I-TAC (also known as CXCL11) to the chemokine receptor CXCR7. CXCR7 antagonist-1 hydrochloride is useful in preventing tumor cell proliferation, tumor formation, inflammatory diseases, and many other diseases (extracted from patent WO2014085490A1, compound 1.128). price>
R-R-4265 Ladarixin sodium CAS No.865625-56-5 Ladarixin sodium (DF 2156A)/CAS No.865625-56-5 is an orally active, allosteric non-competitive and dual CXCR1 and CXCR2 antagonist. Ladarixin sodium can be used for the research of COPD and asthma. price>
R-R-4266 ATI-2341 TFA ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs). price>
R-R-4267 USL311 CAS No.1373268-67-7 USL311/CAS No.1373268-67-7 is a potent and selective CXCR4 antagonist, with anti-tumor activity. USL311 prevents the binding of stromal-cell derived factor-1 (SDF-1 or CXCL12) to CXCR4. price>
R-R-4268 CXCR2-IN-2 CAS No.1838123-21-9 CXCR2-IN-2/CAS No.1838123-21-9 is a selective, brain penetrant, and orally bioavailable CXCR2 antagonist (IC50=5.2 nM/1 nM in β-arrestin assay/CXCR2 Tango assay, respectively). CXCR2-IN-2 displays ~730-fold selectivity over CXCR1 and >1900-fold selectivity over all other chemokine receptors. CXCR2-IN-2 inhibits human whole blood Gro-α induced CD11b expression with an IC50 of 0.04 μM. price>
R-R-4269 Ulocuplumab CAS No.1375830-34-4 Ulocuplumab (Anti-Human CXCR4 Recombinant Antibody/BMS-936564/MDX1338)/CAS No.1375830-34-4 is a fully human IgG4 anti-CXCR4 antibody. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. price>